Ambrisentan
Endothelin Receptor Antagonist — CARDIOVASCULAR SYSTEM
Also known as: letairis, LU 208075, LU208075, volibris
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Ambrisentan is an ofp drug in the Endothelin Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2007. Its mechanism of action is classified as Endothelin Receptor Antagonists. DrugCentral lists 2 molecular targets, including EDNRA and EDNRB. Recorded indications include Pulmonary arterial hypertension.
- Approval status: ofp (first approved 2007 by the FDA).
- Drug class: Endothelin Receptor Antagonist.
- Mechanism of action: Endothelin Receptor Antagonists.
- Molecular targets: EDNRA and EDNRB (2 listed in DrugCentral).
- Indications: Pulmonary arterial hypertension.
- ATC code: C02KX02 (Antihypertensives for pulmonary arterial hypertension).
- Molecular formula: C22H22N2O4; molecular weight 378.43 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Pulmonary arterial hypertension
Contraindications (9)
- Anemia
- Body fluid retention
- Breastfeeding (mother)
- Chronic heart failure
- Edema
- Liver function tests abnormal
- Oligozoospermia
- Pregnancy, function
- Pulmonary veno-occlusive disease
Mechanism & targets
| Mechanism of action (MoA) | Endothelin Receptor Antagonists |
|---|---|
| Established pharmacologic class | Endothelin Receptor Antagonist |
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Endothelin-1 receptor | EDNRA | antagonist | Ki 9.65 |
| Endothelin B receptor | EDNRB | antagonist | Ki 6.98 |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2021-03-23 | PMDA | — | GlaxoSmithKline K.K. | Yes |
| 2019-06-20 | EMA | — | MYLAN SAS | |
| 2007-06-15 | FDA | — | GILEAD | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
C02KX02 | CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › OTHER ANTIHYPERTENSIVES › Antihypertensives for pulmonary arterial hypertension |
C02KX52 | CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › OTHER ANTIHYPERTENSIVES › Antihypertensives for pulmonary arterial hypertension |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Dyspnoea | 6403.3 |
| Fluid retention | 3816.7 |
| Death | 3327.4 |
| Headache | 2639.3 |
| Pain in jaw | 2595.8 |
| Nasal congestion | 2476.9 |
| Pulmonary arterial hypertension | 2088.8 |
| Right ventricular failure | 1789.9 |
| Hypervolaemia | 1627.7 |
| Pulmonary hypertension | 1594.9 |
| Flushing | 1463.0 |
| Oedema | 1431.1 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Ambrisentan is on its molecule page.
| Molecular formula | C22H22N2O4 |
|---|---|
| Molecular weight | 378.43 g/mol |
| CAS number | 177036-94-1 |
| InChIKey | OUJTZYPIHDYQMC-LJQANCHMSA-N |
| PubChem CID | 6918493 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Ambrisentan used for?
DrugCentral lists the following indications for Ambrisentan: Pulmonary arterial hypertension.
How does Ambrisentan work?
Ambrisentan is classified as Endothelin Receptor Antagonists; its molecular targets in DrugCentral include EDNRA (antagonist) and EDNRB (antagonist).
When was Ambrisentan first approved?
Ambrisentan was first approved by the FDA in 2007.
What drug class does Ambrisentan belong to?
Ambrisentan is in the Endothelin Receptor Antagonist class.
What is the chemical formula of Ambrisentan?
Ambrisentan has the molecular formula C22H22N2O4 and a molecular weight of 378.43 g/mol.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4337 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1111 — compound record and bioactivity
- PubChem CID 6918493 — chemical identifiers
- DrugBank DB06403 — drug record
- FDA UNII HW6NV07QEC — substance identity
- DailyMed: FDA labels for Ambrisentan — current prescribing information (label search)
- UniProt P25101 (EDNRA) — target protein
- UniProt P24530 (EDNRB) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.